Tanaka K, Hirasawa T. Gastric adenocarcinoma and proximal polyposis of the stomach. N Engl J Med. 2025;392:e29.
Google ScholarÂ
Zhang X, Wang J, Wang G, Zhang Y, Fan Q, Lu C, et al. First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial. JAMA. 2025;333:1305–14.
Google ScholarÂ
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B. et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31:1163–70.
Google ScholarÂ
Wizenty J, Sigal M. Helicobacter pylori, microbiota and gastric cancer-principles of microorganism-driven carcinogenesis. Nat Rev Gastroenterol Hepatol. 2025;22:296–313.
Google ScholarÂ
Ma H, Srivastava S, Ho SWT, Xu C, Lian BSX, Ong X, et al. Spatially resolved tumor ecosystems and cell states in gastric adenocarcinoma progression and evolution. Cancer Discov. 2025;15:767–92.
Google ScholarÂ
Yeoh KG, Tan P. Mapping the genomic diaspora of gastric cancer. Nat Rev Cancer. 2022;22:71–84.
Google ScholarÂ
An M, Mehta A, Min BH, Heo YJ, Wright SJ, Parikh M, et al. Early immune remodeling steers clinical response to first-line chemoimmunotherapy in advanced gastric cancer. Cancer Discov. 2024;14:766–85.
Google ScholarÂ
Mao X, Ji T, Liu A, Weng Y. ELK4-mediated lncRNA SNHG22 promotes gastric cancer progression through interacting with EZH2 and regulating miR-200c-3p/Notch1 axis. Cell Death Dis. 2021;12:957.
Google ScholarÂ
Mao X, Liu T, Yu S, Wei Y, Zhou C, Kuai X. CEACAM6 facilitates gastric cancer progression through upregulating SLC27A2. Cancer Gene Ther. 2025;32:51–60.
Google ScholarÂ
Zhang B, Niu W, Dong HY, Liu ML, Luo Y, Li ZC. Hypoxia induces endothelial‑mesenchymal transition in pulmonary vascular remodeling. Int J Mol Med. 2018;42:270–8.
Google ScholarÂ
Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, et al. NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Sci Transl Med. 2018;10.
Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, et al. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. Eur J Gastroenterol Hepatol. 2017;29:289–96.
Google ScholarÂ
Su B, Zhao W, Shi B, Zhang Z, Yu X, Xie F, et al. Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7. Mol Cancer. 2014;13:206.
Google ScholarÂ
Goncalves-Ribeiro S, Sanz-Pamplona R, Vidal A, Sanjuan X, Guillen Diaz-Maroto N, Soriano A, et al. Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling. Ann Oncol. 2017;28:2160–8.
Google ScholarÂ
Shen H, Wang L, Chen Q, Xu J, Zhang J, Fang L, et al. The prognostic value of COL3A1/FBN1/COL5A2/SPARC-mir-29a-3p-H19 associated ceRNA network in Gastric Cancer through bioinformatic exploration. J Cancer. 2020;11:4933–46.
Google ScholarÂ
Yuan X, Xiao Y, Yu D. Turn cold tumors hot by reprogramming the tumor microenvironment. Nat Biotechnol. 2025;43:466–70.
Google ScholarÂ
Baghdadi MB, Houtekamer RM, Perrin L, Rao-Bhatia A, Whelen M, Decker L, et al. PIEZO-dependent mechanosensing is essential for intestinal stem cell fate decision and maintenance. Science. 2024;386:eadj7615.
Google ScholarÂ
Miller EJ, Epstein EH Jr, Piez KA. Identification of three genetically distinct collagens by cyanogen bromide cleavage of insoluble human skin and cartilage collagen. Biochem Biophys Res Commun. 1971;42:1024–9.
Google ScholarÂ
Valkkila M, Melkoniemi M, Kvist L, Kuivaniemi H, Tromp G, Ala-Kokko L. Genomic organization of the human COL3A1 and COL5A2 genes: COL5A2 has evolved differently than the other minor fibrillar collagen genes. Matrix Biol. 2001;20:357–66.
Google ScholarÂ
Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteom. 2014;13:397–406.
Google ScholarÂ
Lv W, Lin Y, Song W, Sun K, Yu H, Zhang Y, et al. Variants of COL3A1 are associated with the risk of stroke recurrence and prognosis in the Chinese population: a prospective study. J Mol Neurosci. 2014;53:196–203.
Google ScholarÂ
Hosseini ST, Nemati F. Identification of GUCA2A and COL3A1 as prognostic biomarkers in colorectal cancer by integrating analysis of RNA-Seq data and qRT-PCR validation. Sci Rep. 2023;13:17086.
Google ScholarÂ
Duval E, Leclercq S, Elissalde JM, Demoor M, Galera P, Boumediene K. Hypoxia-inducible factor 1alpha inhibits the fibroblast-like markers type I and type III collagen during hypoxia-induced chondrocyte redifferentiation: hypoxia not only induces type II collagen and aggrecan, but it also inhibits type I and type III collagen in the hypoxia-inducible factor 1alpha-dependent redifferentiation of chondrocytes. Arthritis Rheum. 2009;60:3038–48.
Google ScholarÂ
Carpenter G, Cohen S. Human epidermal growth factor and the proliferation of human fibroblasts. J Cell Physiol. 1976;88:227–37.
Google ScholarÂ
Shen T, Gao K, Miao Y, Hu Z. Exogenous growth factors enhance the expression of cola1, cola3, and Elastin in fibroblasts via activating MAPK signaling pathway. Mol Cell Biochem. 2018;442:203–10.
Google ScholarÂ
Shaikh G, Zhang J, Perez-Aso M, Mediero A, Cronstein B. Adenosine A(2A) receptor promotes collagen type III synthesis via beta-catenin activation in human dermal fibroblasts. Br J Pharm. 2016;173:3279–91.
Google ScholarÂ
Mi Y, Wang W, Lu J, Zhang C, Wang Y, Ying H, et al. Proteasome-mediated degradation of collagen III by cortisol in amnion fibroblasts. J Mol Endocrinol. 2018;60:45–54.
Google ScholarÂ
Habara M, Shimada M. Estrogen receptor alpha revised: expression, structure, function, and stability. Bioessays. 2022;44:e2200148.
Google ScholarÂ
Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010;16:2702–8.
Google ScholarÂ
Kim JK, Xu Y, Xu X, Keene DR, Gurusiddappa S, Liang X, et al. A novel binding site in collagen type III for integrins alpha1beta1 and alpha2beta1. J Biol Chem. 2005;280:32512–20.
Google ScholarÂ
Wang XQ, Tang ZX, Yu D, Cui SJ, Jiang YH, Zhang Q, et al. Epithelial but not stromal expression of collagen alpha-1(III) is a diagnostic and prognostic indicator of colorectal carcinoma. Oncotarget. 2016;7:8823–38.
Google ScholarÂ
Hanley CJ, Noble F, Ward M, Bullock M, Drifka C, Mellone M, et al. A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. Oncotarget. 2016;7:6159–74.
Google ScholarÂ
Yuan L, Shu B, Chen L, Qian K, Wang Y, Qian G, et al. Overexpression of COL3A1 confers a poor prognosis in human bladder cancer identified by co-expression analysis. Oncotarget. 2017;8:70508–20.
Google ScholarÂ
Xiao JH, Xu LZ, Ning JZ, Cheng F. Unveiling ADAMTS12: a key driver of bladder cancer progression via COL3A1-Mediated activation of the FAK/PI3K/AKT signaling pathway. J Biol Chem. 2025;301:108155.
Google ScholarÂ
